Shinpoong Pharmaceutical Co Ltd (019175) - Total Liabilities
Based on the latest financial reports, Shinpoong Pharmaceutical Co Ltd (019175) has total liabilities worth ₩79.62 Billion KRW (≈ $53.96 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Shinpoong Pharmaceutical Co Ltd strategic investment ratio to see how much of total assets are deployed in long-term investments.
Shinpoong Pharmaceutical Co Ltd - Total Liabilities Trend (2014–2025)
This chart illustrates how Shinpoong Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 019175 total assets.
Shinpoong Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Shinpoong Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Liberty TripAdvisor Holdings, Inc
NASDAQ:LTRPA
|
USA | $2.22 Billion |
|
Jui Li Enterprise Co Ltd
TW:1512
|
Taiwan | NT$2.10 Billion |
|
Shreyans Industries Limited
NSE:SHREYANIND
|
India | Rs2.07 Billion |
|
Eastern Metals Ltd
AU:EMS
|
Australia | AU$317.26K |
|
Masterkool International Public Company Limited
BK:KOOL
|
Thailand | ฿411.16 Million |
|
FGI Industries Ltd
NASDAQ:FGI
|
USA | $52.74 Million |
|
Southern Fertilizer JSC
VN:SFG
|
Vietnam | ₫1.31 Trillion |
|
London City Equities Ltd
AU:LCE
|
Australia | AU$2.99 Million |
Liability Composition Analysis (2014–2025)
This chart breaks down Shinpoong Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 019175 equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.20 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shinpoong Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shinpoong Pharmaceutical Co Ltd (2014–2025)
The table below shows the annual total liabilities of Shinpoong Pharmaceutical Co Ltd from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩81.74 Billion ≈ $55.39 Million |
-2.70% |
| 2024-12-31 | ₩84.00 Billion ≈ $56.93 Million |
+5.93% |
| 2023-12-31 | ₩79.30 Billion ≈ $53.74 Million |
+157.66% |
| 2022-12-31 | ₩30.78 Billion ≈ $20.86 Million |
-19.06% |
| 2021-12-31 | ₩38.03 Billion ≈ $25.77 Million |
-66.30% |
| 2020-12-31 | ₩112.82 Billion ≈ $76.46 Million |
-34.02% |
| 2019-12-31 | ₩170.99 Billion ≈ $115.87 Million |
-1.43% |
| 2018-12-31 | ₩173.47 Billion ≈ $117.56 Million |
-1.16% |
| 2017-12-31 | ₩175.50 Billion ≈ $118.93 Million |
-12.09% |
| 2016-12-31 | ₩199.64 Billion ≈ $135.29 Million |
-7.52% |
| 2015-12-31 | ₩215.87 Billion ≈ $146.29 Million |
-0.88% |
| 2014-12-31 | ₩217.78 Billion ≈ $147.59 Million |
-- |
About Shinpoong Pharmaceutical Co Ltd
Shinpoong Pharmaceutical Co.,Ltd, together with its subsidiaries, manufactures and sells pharmaceutical products in South Korea. The company offers cephalosporin antibiotics; penicillin antibiotics; and finished products, as well as antivirals, anticancer drugs, painkillers, anti-inflammatory products, and anthelmintics. It provides active pharmaceutical ingredients; Pyramax, an anti-malarial dru… Read more